All In Biotech

Drug Trial Radar · NCT04562766

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 232 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

232

Actual

Start

Dec 14, 2020

Primary completion

Jan 15, 2025

Study completion Sep 2, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a randomized, double-blind study of rilzabrutinib in patients with persistent or chronic ITP, with an average platelet count of \<30,000/μL (and no single platelet count \>35,000/μL) on two counts at least 5 days apart in the 14 days before treatment begins. Patients received rilzabrutinib or placebo 400mg twice daily. For each patient, the study lasted up to 60 weeks from the start of the Screening Period to the End of Study (EOS) visit. This included Screening (up to 4 weeks) through a 12 to 24-week Blinded Treatment Period followed by a 28-week Open-Label Period. Followed by a 4-week post dose follow-up. For adult participants, the maximum duration of the long-term extension (LTE) period was 12 months from the date of the last adult participant to enter the LTE. For pediatric participants, the maximum duration of the LTE period was 12 months from the date of the last pediatric participant to enter the LTE.

Conditions

  • Immune Thrombocytopenia

Interventions

  • RilzabrutinibDrug

    400mg Caplet

  • PlaceboDrug

    400mg Caplet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DB Period: Percentage of Participants With Durable Platelet Response Per Guidance in Regions Except European Union and United KingdomTime frame: Up to 24 weeks
  2. DB Period: Percentage of Participants With Durable Platelet Response Per Guidance in European Union and United KingdomTime frame: Up to 24 weeks

Locations

155 sites in 26 countries. Site status is shown where the registry gives one.

  • University of Southern California_Investigational Site Number 84024

    Los Angeles, California

  • UCSF Benioff Children's Hospital San Francisco_Investigational Site Number 84020

    San Francisco, California

  • Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center_Investigational Site Number 84037

    Torrance, California

  • The Oncology Institute of Hope and Innovation_Investigational Site Number 84031

    Whittier, California

  • Children's Hospital Colorado_Investigational Site Number 84025

    Aurora, Colorado

  • IMMUNOe International Research Centers_Investigational Site Number 84028

    Centennial, Colorado

  • ASCLEPES Research Centers_Investigational Site Number 84023

    Weeki Wachee, Florida

  • Children's Healthcare of Atlanta_Investigational Site Number 84034

    Atlanta, Georgia

  • Rush University Medical Center_Investigational Site Number 84029

    Chicago, Illinois

  • University of Louisville - James Graham Brown Cancer Center_Investigational Site Number 84033

    Louisville, Kentucky

  • Massachusetts General Hospital Site Number : 84038

    Boston, Massachusetts

  • Montefiore Medical Center_Investigational Site Number 84032

    The Bronx, New York

  • University Hospitals Cleveland Medical Center Site Number : 84036

    Cleveland, Ohio

  • Cleveland Clinic_Investigational Site Number 84026

    Cleveland, Ohio

  • The Children's Hospital of Philadelphia (CHOP)_Investigational Site Number 84027

    Philadelphia, Pennsylvania

  • University of Utah-Huntsman Cancer Institute_Investigational Site Number 84035

    Salt Lake City, Utah

  • University of Washington Medical Centre Site Number : 84041

    Seattle, Washington

  • Investigational Site Number : 3209

    Corrientes, Argentina

  • Investigational Site Number : 3208

    San Juan, Argentina

  • Investigational Site Number : 3206

    Capital Federal, Buenos Aires, Argentina

  • Investigational Site Number : 3211

    La Plata, Buenos Aires, Argentina

  • Investigational Site Number : 3205

    Córdoba, Córdoba Province, Argentina

  • Investigational Site Number : 3607

    Kogarah, New South Wales, Australia

  • Investigational Site Number : 3608

    Westmead, New South Wales, Australia

  • Investigational Site Number : 3611

    Brisbane, Queensland, Australia

  • Investigational Site Number : 3609

    Adelaide, South Australia, Australia

  • Investigational Site Number : 3606

    Frankston, Victoria, Australia

  • Investigational Site Number : 3610

    Perth, Western Australia, Australia

  • Investigational Site Number : 4005

    Graz, Austria

  • Investigational Site Number : 4004

    Leoben, Austria

  • Investigational Site Number : 4001

    Linz, Austria

  • Investigational Site Number : 4003

    Steyr, Austria

  • Investigational Site Number : 4002

    Vienna, Austria

  • CEMEC Oncologica do Brasil Site Number : 7606

    Belém, Brazil

  • HEMORIO - Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti Site Number : 7609

    Rio de Janeiro, Brazil

  • Hospital do Servidor Publico Estadual de Sao Paulo Site Number : 7607

    São Paulo, Brazil

  • Hospital Sao Rafael Instituto D'Or da Bahia Site Number : 7608

    Salvador, Estado de Bahia, Brazil

  • Uniao Oeste Paranaense de Estudos e Combates ao Cancer Site Number : 7610

    Cascavel, Paraná, Brazil

  • Hospital De Clinicas De Porto Alegre Site Number : 7605

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Santa Marcelina Site Number : 7611

    São Paulo, São Paulo, Brazil

Showing 40 of 155 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.